Kai M - Search Results

1

Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer.

Onishi H, Kai M, Odate S, Iwasaki H, Morifuji Y, Ogino T, Morisaki T, Nakashima Y, Katano M. Onishi H, et al. Among authors: kai m. Cancer Sci. 2011 Jun;102(6):1144-50. doi: 10.1111/j.1349-7006.2011.01912.x. Epub 2011 Mar 15. Cancer Sci. 2011. PMID: 21338440 Free article.

2

Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer.

Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T, Tanaka M, Onishi H, Katano M. Souzaki M, et al. Among authors: kai m. Cancer Sci. 2011 Feb;102(2):373-81. doi: 10.1111/j.1349-7006.2010.01779.x. Epub 2010 Nov 22. Cancer Sci. 2011. PMID: 21091847 Free article.

3

Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.

Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M. Kai M, et al. Cancer Sci. 2011 Dec;102(12):2132-8. doi: 10.1111/j.1349-7006.2011.02063.x. Epub 2011 Sep 14. Cancer Sci. 2011. PMID: 21838786 Free article.

4

Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.

Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M. Onishi H, et al. Among authors: kai m. Cancer Sci. 2012 Jul;103(7):1272-9. doi: 10.1111/j.1349-7006.2012.02297.x. Epub 2012 May 17. Cancer Sci. 2012. PMID: 22486854 Free PMC article.

5

NOTCH4 is a potential therapeutic target for triple-negative breast cancer.

Nagamatsu I, Onishi H, Matsushita S, Kubo M, Kai M, Imaizumi A, Nakano K, Hattori M, Oda Y, Tanaka M, Katano M. Nagamatsu I, et al. Among authors: kai m. Anticancer Res. 2014 Jan;34(1):69-80. Anticancer Res. 2014. PMID: 24403446

6

Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.

Kubo M, Umebayashi M, Kurata K, Mori H, Kai M, Onishi H, Katano M, Nakamura M, Morisaki T. Kubo M, et al. Among authors: kai m. Anticancer Res. 2018 Jul;38(7):4273-4279. doi: 10.21873/anticanres.12724. Anticancer Res. 2018. PMID: 29970561

7

Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.

Zaguirre K, Kai M, Kubo M, Yamada M, Kurata K, Kawaji H, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Morisaki T, Mori H, Oda Y, Chen S, Moriyama T, Shimizu S, Nakamura M. Zaguirre K, et al. Among authors: kai m. Cancer Med. 2021 Mar;10(5):1605-1613. doi: 10.1002/cam4.3713. Epub 2021 Jan 15. Cancer Med. 2021. PMID: 33452761 Free PMC article.

8

Neoantigens elicit T cell responses in breast cancer.

Morisaki T, Kubo M, Umebayashi M, Yew PY, Yoshimura S, Park JH, Kiyotani K, Kai M, Yamada M, Oda Y, Nakamura Y, Morisaki T, Nakamura M. Morisaki T, et al. Among authors: kai m. Sci Rep. 2021 Jun 30;11(1):13590. doi: 10.1038/s41598-021-91358-1. Sci Rep. 2021. PMID: 34193879 Free PMC article. Clinical Trial.

9

Genetic medicine is accelerating in Japan.

Hayashi S, Kubo M, Kaneshiro K, Kai M, Yamada M, Morisaki T, Takao Y, Shimazaki A, Shikada S, Nakamura M. Hayashi S, et al. Among authors: kai m. Breast Cancer. 2022 Jul;29(4):659-665. doi: 10.1007/s12282-022-01342-4. Epub 2022 Feb 21. Breast Cancer. 2022. PMID: 35191009 Free PMC article.

10

Significance of the Multi-gene Panel myRisk in Japan.

Hayashi S, Kubo M, Matsuzaki S, Kai M, Morisaki T, Yamada M, Kaneshiro K, Takao Y, Shimazaki A, Nagayoshi K, Mizuuchi Y, Nakamura M. Hayashi S, et al. Among authors: kai m. Anticancer Res. 2022 Aug;42(8):4097-4102. doi: 10.21873/anticanres.15907. Anticancer Res. 2022. PMID: 35896222

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

798 results

Search Page